News

Genprex is Defining a New Immunogene Therapy that Could Change the Course of Cancer

Genprex is raising the standard in cancer treatment by developing what it calls an “immunogene therapy,” which harnesses the power of immunotherapy’s immunomodulation through the delivery of a gene therapy.

Read More

Independent Researchers Find Genprex’s TUSC2 Prevents Tumor Growth in Triple-Negative Breast Cancer

Independent researchers reported in a recent study that TUSC2, a tumor suppressor gene and the active agent in Genprex’s Oncoprex™ immunogene therapy, prevented tumor growth in triple-negative breast cancer (TNBC).

Read More

Genprex to Present at the H.C. Wainwright 21st Annual Global Investment Conference

Genprex’s Chairman and Chief Executive Officer, Rodney Varner, will lead the company's presentation on September 9, 2019 in New York City.

Read More

Genprex Provides Forward Looking Guidance and Updates on Corporate Activities, Publishes New Corporate Deck

These anticipated milestones and future guidance are incorporated into the latest update of the company’s corporate presentation, which can be found at Genprex.com.

Read More

Pfizer’s Half-Billion-Dollar Manufacturing Facility Demonstrates Commitment to Gene Therapy

The passion for gene therapy and the new era of cell and gene-based medicine has made its way to the mainstream for treatment of serious diseases.

Read More

Genprex to Present at the RHK Capital 4th Annual Disruptive Growth Conference

Genprex's Chairman and Chief Executive Officer, Rodney Varner, is scheduled to present at the 4th Annual Disruptive Growth Conference in New York City on September 4, 2019.

Read More

Genprex Demonstrates Growth and Expansion Through Recent Achievements

Company’s recent performance sets path for future milestones, commercialization

Read More

Genprex Manufacturing Partner Aldevron Completes Significant Step in Manufacturing for Oncoprex™ Clinical Development Program

Genprex's newly manufactured plasmids will be used in clinical trials evaluating Oncoprex™ in combination with targeted therapies and immunotherapies.

Read More

Genprex Begins Next Phase of Drug Branding Program

Genprex has initiated the first phase of branding its lead drug candidate and has completed the creation and submission of non-proprietary drug name selections to the American Medical Association’s United States Adopted Names (USAN) Council.

Read More

A Potential NSCLC Treatment for Large Patient Populations

Genprex is working on developing its initial drug candidate for NSCLC that would potentially benefit a large patient population who cannot currently benefit from approved therapies.

Read More